Abstract

A potential microtubule destabilising series of new indolizine derivatives was synthesised and tested for their anticancer activity against a panel of 60 human cancer cell lines. Compounds 11a, 11b, 15a, and 15j showed a broad spectrum of growth inhibitory activity against cancer cell lines representing leukaemia, melanoma and cancer of lung, colon, central nervous system, ovary, kidney, breast, and prostate. Among them, compound 11a was distinguishable by its excellent cytostatic activity, showing GI₅₀ values in the range of 10–100 nM on 43 cell lines. The less potent compounds 15a and 15j in terms of GI₅₀ values showed a high cytotoxic effect against tested colon cancer, CNS cancer, renal cancer and melanoma cell lines and only on few cell lines from other types of cancer. In vitro assaying revealed tubulin polymerisation inhibition by all active compounds. Molecular docking showed good complementarity of active compounds with the colchicine binding site of tubulin.

摘要

合成了潜在的微管失稳系列新吲哚嗪衍生物，并测试了它们对一组60种人类癌细胞系的抗癌活性。化合物11a，11b，15a和15j对代表白血病，黑色素瘤和肺癌，结肠癌，中枢神经系统，卵巢，肾脏，乳腺癌和前列腺癌的癌细胞系显示出广泛的生长抑制活性。其中，化合物11a具有出色的细胞抑制活性，在43种细胞系中显示的GI ₅₀值在10-100 nM范围内。根据GI _50，效力较低的化合物15a和15j值显示出对测试的结肠癌，中枢神经系统癌，肾癌和黑色素瘤细胞系具有高细胞毒性作用，并且仅对其他类型癌症中的少数细胞系有作用。体外测定显示所有活性化合物均抑制微管蛋白聚合。分子对接显示活性化合物与微管蛋白的秋水仙碱结合位点具有良好的互补性。